Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Feb, 2014 | Pages:
64 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Les Laboratoires Servier SAS - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Les Laboratoires Servier SAS - Product Pipeline Review - 2014', provides an overview of the Les Laboratoires Servier SAS's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Les Laboratoires Servier SAS's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Les Laboratoires Servier SAS including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Les Laboratoires Servier SAS's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Les Laboratoires Servier SAS's pipeline products Reasons to buy - Evaluate Les Laboratoires Servier SAS's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Les Laboratoires Servier SAS in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Les Laboratoires Servier SAS's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Les Laboratoires Servier SAS and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Les Laboratoires Servier SAS - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Les Laboratoires Servier SAS and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 Les Laboratoires Servier SAS Snapshot 6 Les Laboratoires Servier SAS Overview 6 Key Information 6 Key Facts 6 Les Laboratoires Servier SAS - Research and Development Overview 7 Key Therapeutic Areas 7 Les Laboratoires Servier SAS - Pipeline Review 10 Pipeline Products by Stage of Development 10 Pipeline Products - Monotherapy 11 Pipeline Products - Combination Treatment Modalities 12 Pipeline Products - Partnered Products 13 Partnered Products/Combination Treatment Modalities 14 Les Laboratoires Servier SAS - Pipeline Products Glance 16 Les Laboratoires Servier SAS - Late Stage Pipeline Products 16 Phase III Products/Combination Treatment Modalities 16 Les Laboratoires Servier SAS - Clinical Stage Pipeline Products 17 Phase II Products/Combination Treatment Modalities 17 Phase I Products/Combination Treatment Modalities 18 Les Laboratoires Servier SAS - Early Stage Pipeline Products 19 Preclinical Products/Combination Treatment Modalities 19 Discovery Products/Combination Treatment Modalities 20 Les Laboratoires Servier SAS - Unknown Stage Pipeline Products 21 Unknown Products/Combination Treatment Modalities 21 Les Laboratoires Servier SAS - Drug Profiles 22 (amlodipine + perindopril) 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 gevokizumab 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 ivabradine 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 lucitanib 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 S-33138 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 S-38093 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 S-38844 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 S-44497 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 abexinostat hydrochloride 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 S-49076 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Drugs To Inhibit Insulin-Regulated AminoPeptidase For Alzheimer's Disease 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Monoclonal Antibodies for Oncology 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Deubiquitinating Enzymes Program 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 NBS-101 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Les Laboratoires Servier SAS - Pipeline Analysis 42 Les Laboratoires Servier SAS - Pipeline Products by Target 42 Les Laboratoires Servier SAS - Pipeline Products by Route of Administration 45 Les Laboratoires Servier SAS - Pipeline Products by Molecule Type 46 Les Laboratoires Servier SAS - Pipeline Products by Mechanism of Action 47 Les Laboratoires Servier SAS - Recent Pipeline Updates 50 Les Laboratoires Servier SAS - Dormant Projects 57 Les Laboratoires Servier SAS - Discontinued Pipeline Products 58 Discontinued Pipeline Product Profiles 58 agomelatine 58 terutroban 58 Les Laboratoires Servier SAS - Company Statement 59 Les Laboratoires Servier SAS - Locations And Subsidiaries 60 Head Office 60 Other Locations & Subsidiaries 60 Appendix 63 Methodology 63 Coverage 63 Secondary Research 63 Primary Research 63 Expert Panel Validation 63 Contact Us 64 Disclaimer 64
List of Tables Les Laboratoires Servier SAS, Key Information 6 Les Laboratoires Servier SAS, Key Facts 6 Les Laboratoires Servier SAS - Pipeline by Indication, 2014 8 Les Laboratoires Servier SAS - Pipeline by Stage of Development, 2014 10 Les Laboratoires Servier SAS - Monotherapy Products in Pipeline, 2014 11 Les Laboratoires Servier SAS - Combination Treatment Modalities in Pipeline, 2014 12 Les Laboratoires Servier SAS - Partnered Products in Pipeline, 2014 13 Les Laboratoires Servier SAS - Partnered Products/ Combination Treatment Modalities, 2014 14 Les Laboratoires Servier SAS - Phase III, 2014 16 Les Laboratoires Servier SAS - Phase II, 2014 17 Les Laboratoires Servier SAS - Phase I, 2014 18 Les Laboratoires Servier SAS - Preclinical, 2014 19 Les Laboratoires Servier SAS - Discovery, 2014 20 Les Laboratoires Servier SAS - Unknown, 2014 21 Les Laboratoires Servier SAS - Pipeline by Target, 2014 43 Les Laboratoires Servier SAS - Pipeline by Route of Administration, 2014 45 Les Laboratoires Servier SAS - Pipeline by Molecule Type, 2014 46 Les Laboratoires Servier SAS - Pipeline Products by Mechanism of Action, 2014 48 Les Laboratoires Servier SAS - Recent Pipeline Updates, 2014 50 Les Laboratoires Servier SAS - Dormant Developmental Projects,2014 57 Les Laboratoires Servier SAS - Discontinued Pipeline Products, 2014 58 Les Laboratoires Servier SAS, Other Locations 60 Les Laboratoires Servier SAS, Subsidiaries 61
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
